Search

Your search keyword '"Fu, Jianhua"' showing total 859 results
Start Over Author "Fu, Jianhua"
859 results on '"Fu, Jianhua"'

101. The prognostic value and molecular properties of tertiary lymphoid structures in oesophageal squamous cell carcinoma

Author

Ling, Yihong, primary, Zhong, Jian, additional, Weng, Zelin, additional, Lin, Guangrong, additional, Liu, Caixia, additional, Pan, Chuqing, additional, Yang, Hong, additional, Wei, Xiaolong, additional, Xie, Xiuying, additional, Wei, Xiaoli, additional, Zhang, Huizhong, additional, Wang, Geng, additional, Fu, Jianhua, additional, and Wen, Jing, additional

Published
2022
Full Text
View/download PDF

111. Prognostic value of recurrence pattern in locally advanced esophageal squamous cell carcinoma: Results from the phase III trial NEOCRTEC5010

Author

Chen, Dong, primary, Kong, Min, additional, Sun, Jiajing, additional, Yang, Hong, additional, Chen, Yuping, additional, Fang, Wentao, additional, Yu, Zhentao, additional, Mao, Weimin, additional, Xiang, Jiaqing, additional, Han, Yongtao, additional, Chen, Zhijian, additional, Yang, Haihua, additional, Wang, Jiaming, additional, Pang, Qingsong, additional, Zheng, Xiao, additional, Yang, Huanjun, additional, Li, Tao, additional, Zhang, Xu, additional, Li, Qun, additional, Wang, Geng, additional, Mao, Teng, additional, Guo, Xufeng, additional, Lin, Ting, additional, Liu, Mengzhong, additional, Witharana, Pasan, additional, Fu, Jianhua, additional, Chen, Baofu, additional, Shen, Jianfei, additional, and Zhu, Chengchu, additional

Published
2022
Full Text
View/download PDF

114. Lymph Node Ratio Improves Prediction of Overall Survival in Esophageal Cancer Patients Receiving Neoadjuvant Chemoradiotherapy: A National Cancer Database Analysis

Author

Zhang, Yajie, primary, Cao, Yuqin, additional, Zhang, Jiahao, additional, Huang, Maosheng, additional, Roy, Pascal, additional, Huang, Binhao, additional, Yang, Hong, additional, Rong, Yi, additional, Chen, Yuping, additional, Zhu, Chengchu, additional, Fang, Wentao, additional, Yu, Zhentao, additional, Mao, Weimin, additional, Xiang, Jiaqing, additional, Han, Yongtao, additional, Lin, Jules, additional, Zhang, Jie, additional, Fu, Jianhua, additional, He, Jie, additional, and Li, Hecheng, additional

Published
2022
Full Text
View/download PDF

123. Clinical significance and outcomes of bilateral and unilateral recurrent laryngeal nerve lymph node dissection in esophageal squamous cell carcinoma: A large‐scale retrospective cohort study

Author

Zhang, Shuishen, primary, Liu, Qianwen, additional, Li, Bin, additional, Jia, Minghan, additional, Cai, Xiaoli, additional, Yang, Weixiong, additional, Liao, Shufen, additional, Wu, Zhongkai, additional, Cheng, Chao, additional, and Fu, Jianhua, additional

Published
2022
Full Text
View/download PDF

126. The Role of Autophagy in Lamellar Body Formation and Surfactant Production in Type 2 Alveolar Epithelial Cells

Author

Li, Xiaoman, primary, Wang, Liang, additional, Hao, Jialin, additional, Zhu, Qingfeng, additional, Guo, Min, additional, Wu, Changjing, additional, Li, Sihui, additional, Guo, Qiqiang, additional, Ren, Qiuhong, additional, Bai, Ning, additional, Yi, Fei, additional, Jiang, Bo, additional, Zhang, Wenyu, additional, Feng, Yanling, additional, Xu, Hongde, additional, Jiang, Han, additional, Zhai, Xiaoyue, additional, Zhang, Guohua, additional, Ji, Hong-long, additional, Yang, Xuesong, additional, Zhang, Dan, additional, Fu, Jianhua, additional, Chang, Jianjun, additional, Song, Xiaoyu, additional, and Cao, Liu, additional

Published
2022
Full Text
View/download PDF

130. Joint analysis of three genome-wide association studies of esophageal squamous cell carcinoma in Chinese populations

Author

Wu, Chen, Wang, Zhaoming, Song, Xin, Feng, Xiao-Shan, Abnet, Christian C, He, Jie, Hu, Nan, Zuo, Xian-Bo, Tan, Wen, Zhan, Qimin, Hu, Zhibin, He, Zhonghu, Jia, Weihua, Zhou, Yifeng, Yu, Kai, Shu, Xiao-Ou, Yuan, Jian-Min, Zheng, Wei, Zhao, Xue-Ke, Gao, She-Gan, Yuan, Zhi-Qing, Zhou, Fu-You, Fan, Zong-Min, Cui, Ji-Li, Lin, Hong-Li, Han, Xue-Na, Li, Bei, Chen, Xi, Dawsey, Sanford M, Liao, Linda, Lee, Maxwell P, Ding, Ti, Qiao, You-Lin, Liu, Zhihua, Liu, Yu, Yu, Dianke, Chang, Jiang, Wei, Lixuan, Gao, Yu-Tang, Koh, Woon-Puay, Xiang, Yong-Bing, Tang, Ze-Zhong, Fan, Jin-Hu, Han, Jing-Jing, Zhou, Sheng-Li, Zhang, Peng, Zhang, Dong-Yun, Yuan, Yuan, Huang, Ying, Liu, Chunling, Zhai, Kan, Qiao, Yan, Jin, Guangfu, Guo, Chuanhai, Fu, Jianhua, Miao, Xiaoping, Lu, Changdong, Yang, Haijun, Wang, Chaoyu, Wheeler, William A, Gail, Mitchell, Yeager, Meredith, Yuenger, Jeff, Guo, Er-Tao, Li, Ai-Li, Zhang, Wei, Li, Xue-Min, Sun, Liang-Dan, Ma, Bao-Gen, Li, Yan, Tang, Sa, Peng, Xiu-Qing, Liu, Jing, Hutchinson, Amy, Jacobs, Kevin, Giffen, Carol, Burdette, Laurie, Fraumeni, Jr, Joseph F, Shen, Hongbing, Ke, Yang, Zeng, Yixin, Wu, Tangchun, Kraft, Peter, Chung, Charles C, Tucker, Margaret A, Hou, Zhi-Chao, Liu, Ya-Li, Hu, Yan-Long, Liu, Yu, Wang, Li, Yuan, Guo, Chen, Li-Sha, Liu, Xiao, Ma, Teng, Meng, Hui, Sun, Li, Li, Xin-Min, Li, Xiu-Min, Ku, Jian-Wei, Zhou, Ying-Fa, Yang, Liu-Qin, Wang, Zhou, Li, Yin, Qige, Qirenwang, Yang, Wen-Jun, Lei, Guang-Yan, Chen, Long-Qi, Li, En-Min, Yuan, Ling, Yue, Wen-Bin, Wang, Ran, Wang, Lu-Wen, Fan, Xue-Ping, Zhu, Fang-Heng, Zhao, Wei-Xing, Mao, Yi-Min, Zhang, Mei, Xing, Guo-Lan, Li, Ji-Lin, Han, Min, Ren, Jing-Li, Liu, Bin, Ren, Shu-Wei, Kong, Qing-Peng, Li, Feng, Sheyhidin, Ilyar, Wei, Wu, Zhang, Yan-Rui, Feng, Chang-Wei, Wang, Jin, Yang, Yu-Hua, Hao, Hong-Zhang, Bao, Qi-De, Liu, Bao-Chi, Wu, Ai-Qun, Xie, Dong, Yang, Wan-Cai, Wang, Liang, Zhao, Xiao-Hang, Chen, Shu-Qing, Hong, Jun-Yan, Zhang, Xue-Jun, Freedman, Neal D, Goldstein, Alisa M, Lin, Dongxin, Taylor, Philip R, Wang, Li-Dong, and Chanock, Stephen J

Published
2014
Full Text
View/download PDF

133. Efficacy of adjuvant chemotherapy on overall survival in patients with lymph node‐positive esophageal squamous cell carcinoma: Is oral chemotherapy promising?

Author

Fang, Shuogui, Zhong, Jian, Mai, Zihang, Li, Tong, Xie, Xiuying, and Fu, Jianhua

Subjects
ADJUVANT chemotherapy, SQUAMOUS cell carcinoma, OVERALL survival, PROPENSITY score matching, CANCER chemotherapy
Abstract

Background: The role of adjuvant chemotherapy in patients with pathological lymph node‐positive (pN+) resectable esophageal squamous cell carcinoma (ESCC) remains unclear. We aimed to explore whether adjuvant chemotherapy could improve the overall survival (OS) of patients with pN+ ESCC and whether oral chemotherapy could be used as an alternative to intravenous chemotherapy. Methods: The patients were divided into two groups: a surgery plus chemotherapy group (S + CT group, 400 patients) and a surgery alone group (S group, 582 patients). Propensity score matching (PSM) was used to create patient groups that were balanced across several covariates (n = 331 in each group). The survival rates of patients receiving oral chemotherapy (69 patients with S‐1 and 68 patients with tegafur tablets) and intravenous chemotherapy (263 patients) were compared using the Kaplan–Meier method. Results: In the overall study cohort, the 3‐year OS was significantly higher in the S + CT group than in the S group (66.3% vs. 49.9%, p < 0.001). These data were confirmed in the matched groups (3‐year OS, 72.9% vs. 62.0%, p < 0.001). Multivariate Cox regression analysis in the matched samples showed that adjuvant chemotherapy was an independent prognostic factor for ESCC (HR: 0.62, 95% CI: 0.50–0.76, p < 0.001). Patients who received oral chemotherapy had a similar OS as patients who received intravenous chemotherapy. Conclusions: Adjuvant chemotherapy could significantly improve the OS of patients with pN+ ESCC, and oral chemotherapy drugs might be a better option because of their similar efficacy but fewer side effects than intravenous chemotherapy. This conclusion warrants further study in prospective, randomized controlled trials. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

134. Long-term Efficacy of Neoadjuvant Chemoradiotherapy Plus Surgery for the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma

Author

Yang, Hong, Liu, Hui, Chen, Yuping, Zhu, Chengchu, Fang, Wentao, Yu, Zhentao, Mao, Weimin, Xiang, Jiaqing, Han, Yongtao, Chen, Zhijian, Yang, Haihua, Wang, Jiaming, Pang, Qingsong, Zheng, Xiao, Yang, Huanjun, Li, Tao, Zhang, Xu, Li, Qun, Wang, Geng, Chen, Baofu, Mao, Teng, Kong, Min, Guo, Xufeng, Lin, Ting, Liu, Mengzhong, and Fu, Jianhua

Subjects
Research, Online First, Original Investigation, Featured
Abstract

Key Points Question Does treatment with neoadjuvant chemoradiotherapy plus surgery improve the long-term survival of patients with locally advanced esophageal squamous cell carcinoma (ESCC) compared with surgery alone? Findings In this randomized clinical trial of 451 patients with locally advanced ESCC, treatment with neoadjuvant chemoradiotherapy plus surgery showed significantly improved 5-year overall survival of 59.9% compared with 49.1% for surgery alone, as well as improved disease-free survival. Meaning In this study, long-term outcomes demonstrated a survival benefit from neoadjuvant chemoradiotherapy followed by surgery compared with surgery alone for the treatment of patients with locally advanced ESCC, indicating that this combination may be considered a standard of care in this patient population., Importance The prognosis of patients with locally advanced esophageal squamous cell carcinoma (ESCC) remains poor after surgery. Neoadjuvant chemoradiotherapy (NCRT) has been shown to potentially improve survival. Objective To compare the treatment efficacy of NCRT plus surgery with surgery alone for long-term survival among patients with locally advanced ESCC. Design, Setting, and Participants The Neoadjuvant Chemoradiotherapy for Esophageal Cancer 5010 study was a multicenter open-label randomized phase 3 clinical trial that enrolled patients between June 1, 2007, and December 31, 2014. Follow-up ended on December 31, 2019. The study was conducted at 8 centers in China. A total of 451 patients aged 18 to 70 years with thoracic ESCC stage T1-4N1M0/T4N0M0 were enrolled and randomized. Data were analyzed from December 1, 2019, to June 30, 2020. Interventions Patients randomized to receive NCRT plus surgery (NCRT group) received preoperative chemotherapy (25 mg/m2 of vinorelbine on days 1 and 8 and 75 mg/m2 of cisplatin on day 1 or 25 mg/m2 of cisplatin on days 1 to 4) every 3 weeks for 2 cycles and concurrent radiotherapy (40.0 Gy, administered in 20 fractions of 2.0 Gy for 5 days per week) followed by surgery. Patients randomized to receive surgery alone (surgery group) underwent surgery after randomization. Main Outcomes and Measures The primary end point was overall survival in the intention-to-treat population. The secondary end point was disease-free survival. Results A total of 451 patients (mean [SD] age, 56.5 [7.0] years; 367 men [81.4%]) were randomized to the NCRT (n = 224) and surgery (n = 227) groups and were eligible for the intention-to-treat analysis. By December 31, 2019, 224 deaths had occurred. The median follow-up was 53.5 months (interquartile range, 18.2-87.4 months). Patients receiving NCRT plus surgery had prolonged overall survival compared with those receiving surgery alone (hazard ratio, 0.74; 95% CI, 0.57-0.97; P = .03), with a 5-year survival rate of 59.9% (95% CI, 52.9%-66.1%) vs 49.1% (95% CI, 42.3%-55.6%), respectively. Patients in the NCRT group compared with the surgery group also had prolonged disease-free survival (hazard ratio, 0.60; 95% CI, 0.45-0.80; P, This randomized clinical trial provides updated outcomes of the Neoadjuvant Chemoradiotherapy for Esophageal Cancer 5010, which examined the long-term efficacy of neoadjuvant chemoradiotherapy plus surgery vs surgery alone for the treatment of patients with esophageal squamous cell carcinoma.

Published
2021

139. Individual patient data meta-analysis of neoadjuvant chemotherapy followed by surgery versus upfront surgery for carcinoma of the oesophagus or the gastro-oesophageal junction

Author

Faron, Matthieu, primary, Cheugoua-Zanetsie, Armel Maurice, additional, Thirion, Pierre, additional, Nankivell, Matthew, additional, Winter, Kathryn, additional, Cunningham, David, additional, Van der Gaast, Ate, additional, Law, Simon, additional, Langley, Ruth, additional, de Vathaire, Florent, additional, Valmasoni, Michele, additional, Mauer, Muriel, additional, Roth, Jack, additional, Gebski, Val, additional, Burmeister, Bryan H., additional, Paoletti, Xavier, additional, van Sandick, Johanna, additional, Fu, Jianhua, additional, Ducreux, Michel, additional, Blanchard, Pierre, additional, Tierney, Jayne, additional, Pignon, Jean-Pierre, additional, and Michiels, Stefan, additional

Published
2021
Full Text
View/download PDF

147. Neoadjuvant programmed death-1 blockade plus chemotherapy in locally advanced esophageal squamous cell carcinoma

Author

Yang, Guozhen, primary, Su, Xiaodong, additional, Yang, Hong, additional, Luo, Guangyu, additional, Gao, Chan, additional, Zheng, Yating, additional, Xie, Wenzhuan, additional, Huang, Mengli, additional, Bei, Ting, additional, Bai, Yuezong, additional, Wang, Zhiqiang, additional, Cai, Peiqiang, additional, He, Haoqiang, additional, Xiang, Jin, additional, Cai, Muyan, additional, Zhang, Yijun, additional, Qu, Chunhua, additional, Fu, Jianhua, additional, Liu, Qianwen, additional, Hu, Yi, additional, Zhong, Jiudi, additional, Huang, Yuanheng, additional, Guo, Qiyu, additional, and Zhang, Xu, additional

Published
2021
Full Text
View/download PDF

148. Abstract 1601: Neoadjuvant programmed death-1 blockade plus chemotherapy in locally advanced esophageal squamous cell carcinoma

Author

Yang, Guozhen, primary, Su, Xiaodong, additional, Yang, Hong, additional, Luo, Guangyu, additional, Gao, Chan, additional, Zheng, Yating, additional, Xie, Wenzhuan, additional, Huang, Mengli, additional, Bai, Yuezong, additional, Wang, Zhiqiang, additional, Cai, Peiqiang, additional, He, Haoqiang, additional, Xiang, Jin, additional, Cai, Muyuan, additional, Zhang, Yijun, additional, Qu, Chunhua, additional, Fu, Jianhua, additional, Liu, Qianwen, additional, Hu, Yi, additional, Zhong, Jiudi, additional, Huang, Yuanheng, additional, Guo, Qiyu, additional, and Zhang, Xu, additional

Published
2021
Full Text
View/download PDF

149. Individual patient data meta-analysis of neoadjuvant chemotherapy followed by surgery versus upfront surgery for carcinoma of the oesophagus or the gastro-oesophageal junction

Author

Faron, Matthieu, Cheugoua-Zanetsie, Armel Maurice, Thirion, Pierre, Nankivell, Matthew, Winter, Kathryn, Cunningham, David, van der Gaast, A. (Ate), Law, Simon, Langley, Ruth, de Vathaire, Florent, Valmasoni, Michele, Mauer, Muriel, Roth, Jack, Gebski, Val, Burmeister, Bryan H., Paoletti, Xavier, van Sandick, Johanna, Fu, Jianhua, Ducreux, Michel, Blanchard, Pierre, Tierney, Jayne, Pignon, Jean Pierre, Michiels, Stefan, Faron, Matthieu, Cheugoua-Zanetsie, Armel Maurice, Thirion, Pierre, Nankivell, Matthew, Winter, Kathryn, Cunningham, David, van der Gaast, A. (Ate), Law, Simon, Langley, Ruth, de Vathaire, Florent, Valmasoni, Michele, Mauer, Muriel, Roth, Jack, Gebski, Val, Burmeister, Bryan H., Paoletti, Xavier, van Sandick, Johanna, Fu, Jianhua, Ducreux, Michel, Blanchard, Pierre, Tierney, Jayne, Pignon, Jean Pierre, and Michiels, Stefan

Abstract

Introduction: Which neoadjuvant treatment for locally advanced thoracic oesophagus (TE) or gastro-oesophageal junction carcinoma is best remains an open question. Randomised controlled trials variously accrued patients with adenocarcinoma and squamous cell carcinoma, making strong conclusions hard to obtain. The primary objective of this individual participant data meta-analysis was to investigate the effect of neoadjuvant chemotherapy on overall survival (OS). Patients and methods: Eligible trials should have closed to accrual before 2016 and compared neoadjuvant chemotherapy and surgery (CS) to surgery alone. All relevant published and unpublished trials were identified via searches of electronic databases, conference proceedings and clinical trial registers. The main end-point was OS. Investigators were contacted to obtain the individual patient data, which was recorded, harmonised and checked. A random-effects Cox model, stratified by trial, was used for meta-analysis and subgroup analyses were preplanned. Results: 16 trials were identified as eligible. Individual patient data were obtained from 12 trial and 2478 patients. CS was associated with an improved OS versus surgery, hazard ratio (HR) = 0.83 [0.72–0.96], p < 0.0001, translating to an absolute benefit of 5.7% at 5-years from 16.8% to 22.5%. Treatment effects did not vary substantially between adenocarcinoma (HR = 0.73 [0.62–0.87]) and squamous cell carcinoma (HR = 0.91 [0.76–1.08], interaction p = 0.26). A somewhat more pronounced effect was observed in gastro-oesophageal junction (HR = 0.68 [0.50–0.93]) versus TE (HR = 0.87 [0.75–1.00], interaction p = 0.07). CS was also associated with a greater disease-free survival (HR = 0.74 [0.64–0.85], p < 0.001). Conclusions: Neoadjuvant chemotherapy conferred a better OS than surgery alone and should be considered in all anatomical location and histological subtypes.

Published
2021

150. Genome-wide association analyses of esophageal squamous cell carcinoma in Chinese identify multiple susceptibility loci and gene-environment interactions

Author

Wu, Chen, Kraft, Peter, Zhai, Kan, Chang, Jiang, Wang, Zhaoming, Li, Yun, Hu, Zhibin, He, Zhonghu, Jia, Weihua, Abnet, Christian C, Liang, Liming, Hu, Nan, Miao, Xiaoping, Zhou, Yifeng, Liu, Zhihua, Zhan, Qimin, Liu, Yu, Qiao, Yan, Zhou, Yuling, Jin, Guangfu, Guo, Chuanhai, Lu, Changdong, Yang, Haijun, Fu, Jianhua, Yu, Dianke, Freedman, Neal D, Ding, Ti, Tan, Wen, Goldstein, Alisa M, Wu, Tangchun, Shen, Hongbing, Ke, Yang, Zeng, Yixin, Chanock, Stephen J, Taylor, Philip R, and Lin, Dongxin

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results